Keynote Session 4: Regulatory Keynote

12:30-1:20 PM, November 23, 2026; Room 10A-D

Speaker
Moderator
  • Satoshi HattoriDepartment of Biomedical Statistics, Graduate School of Medicine, The University of Osaka, Japan

The Future of Oncology Drug Development: A Regulatory Perspective from Japan

Speaker: Yasuhiro Fujiwara, Pharmaceuticals and Medical Devices Agency (PMDA), Japan
Biography

Yasuhiro Fujiwara

Dr Yasuhiro Fujiwara has been Chief Executive of the Pharmaceuticals and Medical Devices Agency (PMDA) since 2019. He actively engages with international regulatory agencies, including the International Coalition of Medicines Regulatory Authorities (ICMRA) for which he served as Vice-Chair from 2019 to 2025. Under his leadership, PMDA has strengthened regulatory collaboration with authorities across Asia, Europe, and North America.

A medical oncologist specializing in breast cancer, Dr Fujiwara was previously Director-General of the Strategic Planning Bureau of the National Cancer Center, and Deputy Director of the National Cancer Center Hospital. Between Jan 2011 and Feb 2013, he was Deputy Secretary-General of the Office of Medical Innovation, Cabinet Secretariat of Japan, and led health policy issues regarding life sciences.

Dr Fujiwara has authored or co-authored over 280 original articles in peer-reviewed journals including Nature Reviews Drug Discovery, Lancet Oncology, Journal of Clinical Oncology, and Annals of Oncology.

Abstract

In recent years, drug development by emerging biopharma companies (EBP) has become the mainstream worldwide, and the business model of drug development has been changing significantly.

To address these circumstances, the Japan Growth Strategy, approved by the Cabinet on July 21, 2026, identifies the following major measures in the fields of drug discovery and advanced medical care: strengthening of human resource development for practical application, international harmonization of pharmaceutical regulations in the field of drug discovery, promotion of reliance, and utilization of the PMDA-ATC (PMDA Asia Training Center for Pharmaceuticals and Medical Devices) and PMDA overseas offices.

This presentation introduces PMDA's initiatives to ensure timely patient access to innovative medical products.


Moderator: Satoshi Hattori

Department of Biomedical Statistics, Graduate School of Medicine, The University of Osaka, Japan
Biography

Satoshi Hattori

Satoshi Hattori is Professor of Biostatistics at The University of Osaka, Japan. His research focuses on statistical methodology for clinical trials and evidence synthesis, with particular interests in survival analysis, meta-analysis, causal inference, and methods for addressing publication bias. He has contributed to the development of statistical methods for the design and analysis of clinical studies, particularly in oncology. He is currently President of the Japanese Region of the International Biometric Society.


Back to agenda ยท All Keynote Sessions